Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models

Authors:

Abstract
No abstract available
Funding Information
  • National Institute of Allergy and Infectious Diseases (AI138195)
  • AstraZeneca
  • National Cancer Institute (R01CA246785)
  • National Institute of General Medical Sciences (GM114179)

This publication has 305 references indexed in Scilit: